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Background: The dynamics of metabolomics in establishing a prediction model using partial least square discriminant
analysis have enabled better disease diagnosis; with emphasis on early detection of diseases. We attempted to
translate the metabolomics model to predict the health status of the Orang Asli community whom we have little
information. The metabolite expressions of the healthy vs. diseased patients (cardiovascular) were compared. A
metabotype model was developed and validated using partial least square discriminant analysis (PLSDA). Cardiovascular
risks of the Orang Asli were predicted and confirmed by biochemistry profiles conducted concurrently.
Results: Fourteen (14) metabolites were determined as potential biomarkers for cardiovascular risks with receiver
operating characteristic of more than 0.7. They include 15S-HETE (AUC = 0.997) and phosphorylcholine (AUC = 0.995).
Seven Orang Asli were clustered with the patients’ group and may have ongoing cardiovascular risks and problems. This
is supported by biochemistry tests results that showed abnormalities in cholesterol, triglyceride, HDL and LDL levels.
Conclusions: The disease prediction model based on metabolites is a useful diagnostic alternative as compared to the
current single biomarker assays. The former is believed to be more cost effective since a single sample run is able to
provide a more comprehensive disease profile, whilst the latter require different types of sampling tubes and blood
volumes.
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Cardiovascular disease (CVD) is known as the major
cause of death worldwide [1]. According to the World
Health Organization report in 2013, 17.3 million deaths
were estimated; and the majority were due to ischemic
heart disease and stroke. The National Health and
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unless otherwise stated.America reported that from 2007 to 2010, the inci-
dence of CVD in adults was found to increase with
age [2]. According to the Department of Statistics
Malaysia, this non-communicable disease has become
one of the major causes of death with increasing per-
centage from the year 2005 to 2008. The National
Health and Nutrition Examination Survey of the United
States of America also predicted that the number of people
who died from CVD would be 23.3 million by 2030,
worldwide.
Lipid measurements including the concentrations of
high-density lipoprotein cholesterol (HDL) and low-density
lipoprotein cholesterol (LDL) were routinely used as indica-
tors to assess cardiovascular risks [3]. Smoking, genetics,tral. This is an Open Access article distributed under the terms of the Creative
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HDL and LDL levels [4]. Moraet al. [5] found that HDL
level was consistently and inversely associated with the inci-
dence of coronary and cardiovascular events across a range
of LDL, where high level of LDL caused higher risk of
CVD. The lipid parameters however provided a narrow
view of the lipid metabolism as reported in the previous
study [3-5]. Alternatively, real time monitoring of the vali-
dated biomarkers comprised of differentially expressed me-
tabolites of a patient is desirable in order to allow more
accurate and early detection.
Metabolomics is one of the core disciplines of systems
biology. It has been integrated into multidisciplinary ap-
proaches to profile changes in small molecules associated
with human diseases. Metabolites are the end-products of
gene expression, which is closely related to protein and
enzymatic reactions. Therefore, metabolites offer a direct
molecular signature of status of cells that reflect changes
in the phenotype and molecular physiology and are useful
for evaluation of the efficacy of medical treatments [6,7].
Recent innovations in instrumentation, bioinformatics
tools and softwares have enable comprehensive analysis
of cellular metabolites and therefore enhance the po-
tential of metabolomics to be adopted for clinical diag-
nostics and industries [8,9]. Advanced techniques, such
as NMR, GCMS/QTOF and UPLCMS/QTOF have allowed
researchers to determine biomarkers for detection and
monitoring of the progress of diseases using urine and
serum samples [10-12]. The dynamics of metabolomics
have enabled a comprehensive real time understanding
on the phenotypic changes relating to disease states, ac-
counting the influence of variations in genes and proteins,
epigenetic regulation and post-translational modifications.
For examples, the changes of 5-OH-tryptophan, 2-OH-
butyric acid and 3-OH-butyric acid, which are involved
in hypoxia, are useful for the early detection of acute
coronary syndrome (ACS) because often time ACS is
detected when the disease is in an advanced and irrevers-
ible stage [13].
The Orang Asli is the indigenous people of Peninsular
Malaysia. They are believed to be among the first people
to have arrived in Peninsular Malaysia by different waves
of migration back to about 50,000y years before present
[14]. They constitute 1.5% of the Malaysian population
and is relatively small in numbers compared to the other
Malaysian ethnics [15]. One of the major concerns of
the Orang Asli population is their numbers are declining.
This leads to the question of what had caused the declining
in numbers of these populations in Peninsular Malaysia.
Over the past three decades, the Orang Asli had under-
gone relocation programs by the Government of Malaysia.
These relocation programs provided the Orang Asli with
better amenities and promises for modern infrastructure.
However, with these relocation programs, the OrangAsli has scant access to foraging, fishing, as well as agri-
culture resulting in life styles that are more sedentary.
This sedentary way of living may have influenced their
health status. The changes of environmental and lifestyles
may bring evolutionary adaptive changes from total de-
pendence on forest resources to reliance on the market
economy [16]. Reports on the health status of the Orang
Asli are also limited due to the difficulty in obtaining vol-
untary participation of the Orang Asli in research. The
health quality of the Orang Asli was reported to be poorer
as compared to the urban people because of the nutri-
tional deficiency and poor hygiene among them [17]. De-
tailed medical records on their health status are lacking,
as they do not have much faith in modern therapy but re-
sort to traditional therapy and self-healing management.
The local authority consequently is facing challenges in
strategizing health care plans for these communities.
We therefore undertake this study to develop a disease-
risk predictive model in an attempt to characterize the
individuals with cardiovascular disease versus healthy
individuals based on the metabolite profiles. Orang Asli
are chosen as subjects in this study due to several reasons.
Based on the findings of several qualitative studies con-
ducted in the 1970’s and 1990’s, low or unreported cases
of coronary artery diseases such as fibrous plaques and
complicated lesions were found among the Orang Asli
[18-20]. In 2010 and 2012, the Orang Asliwere reported to
suffer from diabetes, obesity and metabolic syndromes
[21,22] but no report on cardiovascular diseases was
reported thus far. From the communication with the
local Orang Asli, there were many cases of sudden
death with unknown reasons which we believed could
be cardiovascular-related events, such as myocardial
infarction.
In addition, as blood sampling from the Orang Asli is
difficult and challenging and routine biochemical analyses
require higher volume of blood sample for determination
of kidney function, liver function and cardiovascular status
of the subject for diagnosis of diseases, metabolomics is
believed to be more appropriate. We had previously re-
ported the use of global metabolomics methods that allow
us to determine the metabotypes of the patients with 200
microliters of serum [23].
Materials and methods
Subjects
The project was approved by the local constitutional
Human Research Ethics Committee of UniversitiTekno-
logi MARA and Department of Orang Asli Develop-
ment (JAKOA). Good clinical practice and Declaration
of Helsinki were followed closely in the study. Prior to
sample collection, the purpose and protocol of the study
were explained to the subjects and written informed
consents were obtained. All the subjects recruited were
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medical officers. Demographic data were also collected.
The subjects were classified into three groups: urban
population of cardiovascular patients with history of myo-
cardial infarction (MI; n = 31) and healthy volunteers (HT;
n = 23), and self-claimed healthy Orang Asli (OA; n = 34).
The thirty-one (31) patients were recruited from the
local hospital. Any patient with other defined illness and
chronic disease was excluded. Thirty-four (34) Orang Asli
recruited do not have any known diseases. All the healthy
volunteers have no current or previous history of cardio-
vascular disease or any chronic disease. Routine biochem-
istry test including liver function test, kidney function test
were performed to ensure they have no abnormality in
these tests. They were not taking any supplement or medi-
cation one week before blood withdrawal.
Sample preparation
Serum samples were used in our study. Protein precipi-
tation and purification of the samples were performed
by adding 600 μl of cold acetonitrile into 200 μl of serum.
The samples were then centrifuged at 10000xg for 10 mi-
nutes at 4°C. The supernatant was then transferred into a
microcentrifuge tube and dried using a vacuum concen-
trator (Eppendorf, Hamburg, Germany).
Global metabolomics using LC/MS-QTOF analysis
Freshly prepared samples were reconstituted with mobile
phase (A 95% dH2O: B 5% ACN). Two microliters of the
samples were injected and analysed by LC/MS-QTOF
(model 6520 Agilent Technologies, SA, USA) using a
ZORBAX Eclipse Plus C18 column (100 mm × 2.1 mm ×
1.8 μm, Agilent Technologies, SA, USA) maintained at
40°C. The system was operated with a flow rate of
0.25 mL/min with solvent A (water with 0.1% formic
acid) and solvent B (acetonitrile with 0.1% formic acid).
A linear gradient was developed over 36 minutes from
5% to 95% of mobile phase (B). The total run time was
48 minutes for each analysis. Electrospray ionization
(ESI) source settings were as follows: V Cap 4000 V,
skimmer 65 V and fragmentor 125 V. The nebulizer was
set at 45 psig and the nitrogen drying gas was set at a flow
rate of 12 L/min. The drying gas temperature was main-
tained at 350°C. Data were collected in a positive ESI
mode and in full scan mode from 100 to 1000m/z. During
the analysis, two reference masses of 121.0509m/z
(C5H4N4) and 922.0098m/z (C18H18O6N3P3F24) were
continuously injected to allow constant accurate mass
correction.
Each sample was analyzed in four replicates. Quality
control (QC) samples were prepared by pooling aliquots
of all the samples analysed. Each QC sample was ana-
lysed independently. QC samples were injected at the
beginning, middle and end of the run to check thesystem’s stability and performance. The performance of
QC was evaluated by calculating the distribution of rela-
tive standard deviation (RSD) of metabolites that are con-
stantly present in 80% of the pooled samples (see
Additional file 1).
Identification of metabolites
Potential metabolite markers for the patients were con-
firmed by targeted MS/MS approach (model 6520 Agilent
Technologies, SA,USA). The experiments were repeated
with chromatographic conditions identical to the primary
global metabolomics analysis. Ions were targeted using
collision-induced dissociation fragmentation (20 V) based
on the previously determined accurate mass. Accurate
mass data and isotopic distributions for the precursor and
product ions were studied and compared to the spec-
tral data of reference compounds from MassBank
database (www.massbank.jp). The spectra for the tar-
geted compounds and its product ion were viewed in
Additional file 2.
Data mining and statistical analysis
The data processing and data analysis were as described
and modified from previous study [24,25]. Metabolite
extraction and data mining were performed using Agilent
MassHunterQualitative Analysis software. Background
noise were excluded and removed from the analysis.
For statistical analysis, the datasets were imported into
Agilent software package (Mass Profiler Professional)
for univariate and multivariate analysis. All data were
normalized. Differences of metabolites in patients and
healthy volunteers were evaluated using t-test (p< 0.005).
Principal component analysis (PCA) was performed to in-
vestigate and visualize the profiles of serum metabolites
between patients and healthy volunteers (Figure 1). Fold
change analysis and volcano plot analysis were performed
to determine the metabolites that passed two-fold changes
with p< 0.005. Area Under Receiver Operating Character-
istic (AUROC) curve analysis of metabolites which were
significantly different were done to validate the results.
The biomarkers were selected if the value of area under is
more than 0.7. Pathway analysis of the metabolites was
performed with Metabolomics Pathway Analysis (MetPA;
http://metpa.metabolomics.ca).
Prediction of metabotypes
Prediction of metabotypes (healthy or cardiovascular dis-
ease traits) among the Orang Asli was done using the
multivariate supervised Partial Least Square-Discriminant
Analysis (PLSDA). Workflow of the prediction model is as
shown in Figure 2. The model was constructed using the
biomarkers differentially expressed between the patients
and healthy volunteers. Cross-validation and permutation
tests (p < 0.001) were performed to validate the accuracy
Figure 1 Principal component analysis of MI and HT (A) and MI, OA and HT (B). PCA represents a separation of MI and HT group (A). B shows
that several Orang Asli were clustered within the MI.
Mohamad et al. Journal of Clinical Bioinformatics  (2015) 5:3 Page 4 of 10of the constructed model with at least 100 of permuta-
tions for each test. For the cross validation, 1/3 of the
samples of each group were used in the training ana-
lysis, while another 2/3 were used for the validation
analysis. Metabotype of the Orang Asli were predicted
from the model based on their metabolite profiles. To
verify the validity and strength of the model, Receiver
Operating Characteristic (ROC) curve analysis was per-
formed to quantify the diagnostic performance of the
fourteen candidate metabolites. Multivariate analysis of
PLSDA, Support Vector Machine (SVM) and Random
Forest (RF) were performed to support the result.
Results
Metabolite profiles and biomarkers discovery
A total of eighty-six (86) metabolites were annotated
and identified from an average of 1658 spectra detected
from LC/MS-QTOF analysis. The identities of the me-
tabolites were determined using the metabolite database(METLIN, Human Metabolome Database, LipidMaps and
KEGG). Significant analysis (t-test, p< 0.005) and fold
change analysis showed that twenty-four (24) metabolites
were significantly different between patients and healthy
volunteers, with at least two-fold differences (Table 1).
Further analysis of the potential biomarkers was per-
formed using the AUROC curve analysis. As a result,
fourteen (14) metabolites were shown to be significantly
different between patients and healthy volunteers with
AUC of at least 0.7. Two (2) metabolites; 15S-HETE
(AUC= 0.997) and phosphorylcholine (AUC= 0.995) with
the highest potential of being the serum biomarkers for pa-
tients were identified. Both metabolites were significantly
up-regulated in the patients as compared to the healthy
volunteers. The performances of the metabolites as poten-
tial biomarkers were validated using PLSDA, Support
Vector Machine (SVM) and Random Forest (RF). Multi-
variate AUROC analysis of PLSDA, SVM and RF were
performed to validate the performance of the biomarkers
Figure 2 Workflow for prediction of phenotype among the OA from the serum metabolite profiles. The workflow was divided into three
parts; validation, training and prediction. The OA data were added to the training model [data of healthy volunteers (HT) and patients (MI)] in
order to predict their phenotype according to the metabolite profiles and identified biomarkers.
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curve analysis (Figure 3). The biomarkers were capable
of discriminating patients from the healthy volunteers
with the AUC of 0.998, 0.998 and 0.991, and average
accuracy of 0.947, 0.961 and 0.963, respectively. These
results denoted that the fourteen (14) serum metabolites
were potential classifiers between the patients and healthy
volunteers.
Two main metabolic pathways were found to be sig-
nificantly altered among patients when compared to
the healthy volunteers. They are metabolisms of lipids
(glycerophospholipid metabolism, fatty acid metabolism,
sphingolipid metabolism, linoleic acid metabolism, arachi-
donic acid metabolism and glycerolipid metabolism) and
amino acids (see Additional file 3).
Metabotypes prediction of the Orang Asli
A cross-validated PLSDA model with satisfactory dis-
criminating ability was constructed using the fourteen
(14) metabolites to assess the metabolic differences be-
tween the patients and healthy volunteers (Figure 4). Val-
idation was obtained from permutation test (n = 100) with
p< 0.05. The prediction model demonstrated that twenty-
seven (27) Orang Asli were predicted to have healthy
status, while the other seven subjects were predicted to
have profiles similar to the patients. Validation usingROC curve analysis showed an AUC value of 0.998 as
the confidence value of the model.
Discussions
PLSDA is widely used as a statistical tool for clustering.
A wide range of metabolomics data can be used to predict
and classify unknown samples using PLSDA approach.
The predictive and orthogonal components supported by
PLSDA facilitate the interpretation of class discrimination
and the prediction of class membership of unknown
samples. Class prediction using metabolomics data can
be used for early diagnosis, prognosis and treatment of
diseases. By using the PLSDA prediction model, we were
able to predict the metabotypes of the Orang Asli accord-
ing to their metabolite profiles with an average accuracy
of 0.998. The prediction model had classified seven (7)
Orang Asli with the cardiovascular patients. Majority of
the Orang Asli were predicted to be healthy. This is in ac-
cordance with what the individuals had claimed and simi-
lar with the results obtained from biochemical analysis.
The biochemistry profiles of the seven (7) subjects showed
that their lipid profiles were in the abnormal ranges which
were associated with cardiovascular risk. They include low
levels of HDL (<1.3 mmol/L), very high level of LDL, high
level of triglycerides (>1.3 mmol/L) and high level of
cholesterol (>5.2 mmol/L) (see Additional file 4).
Table 1 Lists of metabolites differentially expressed among the patients (MI) and healthy volunteers (HT)
Class of metabolite Metabolite p-value (p= 0.005) Log fold change AUC Sensitivity Specificity
Lipids 8,11,14-nonadecatriynoic acid 3.72E-11 -13.01 0.727 0.8 0.8
18-oxo-nonadecanoic acid 1.17E-05 -3.30 0.691 0.8 0.6
5,8-heptadecadiynoic acid 1.28E-18 -4.29 0.754 0.9 0.7
19-methyl-heneicosanoic acid 4.37E-08 -2.78 0.680 0.7 0.5
Methyl 12,13-epoxy-9,15-octadecadienoic acid 4.61E-05 1.14 0.776 0.7 0.7
5,8,11,14-Docosatetraynoic acid 7.49E-10 1.44 0.861 0.8 0.8
2E,5Z,8Z,11Z,14Z-eicosapentaenoic acid 4.66E-06 5.20 0.909 0.8 0.8
14-methyl-8-hexadecen-1-ol 1.07E-07 5.52 0.689 0.5 0.8
15(S)-HETE 6.18E-15 11.04 0.997 1.0 1.0
Prostaglandin E2 2.58E-06 2.86 0.910 0.8 0.9
Vitamin K1 2,3-epoxide 1.11E-05 1.74 0.679 0.6 0.8
24,25-Dihydroxyvitamin D 3.48E-06 -2.07 0.874 0.8 0.8
21-Deoxycortisol 3.97E-09 -2.90 0.688 0.7 0.7
C22 Sulfatide 7.06E-11 -8.73 0.766 0.8 0.8
1-(9Z-heptadecenoyl)-2-docosanoyl-sn-glycerol 2.33E-03 -1.95 0.655 0.8 0.5
1-(9Z,12Z-heptadecadienoyl)-2-(9Z,12Z-
octadecadienoyl)-sn-glycerol
1.72E-04 2.63 0.681 0.8 0.7
Phosphorylcholine 5.31E-17 14.04 0.995 1.0 1.0
GPCho(16:1(9E)/0:0) 1.61E-05 5.22 0.737 0.9 0.6
GPCho(16:1(9Z)/2:0) 3.39E-05 1.96 0.881 0.8 0.8
GPCho(O-18:1(9Z)/0:0) 2.10E-04 2.23 0.869 0.8 0.8
Others Indoleacetaldehyde 4.05E-07 -5.96 0.751 0.9 0.8
Inosine 1.20E-04 -4.85 0.652 0.6 0.9
Biliverdin IX 1.83E-06 -3.51 0.665 0.8 0.6
L-Urobilinogen 1.48E-05 5.32 0.635 0.8 0.8
Significant analysis was performed using t-test unequal variance (p<0.005). The (-) Fold change value indicates the down regulation of the metabolite in MI, while
(+) fold change value indicates the up regulation of metabolite in the MI when compared to HT.
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form is that only a small volume of blood is required as
compared to the routine biochemical assays which re-
quire larger volume of blood samples. This shows that
LC/MS-QTOF is a sensitive method and appropriate in
studies alike, where blood samples are difficult to obtain.
This is especially important in conserved communities
like the Orang Asli, where many of them refused to pro-
vide large volume of blood for medical examination.
Lipid profiles including triglycerides, total cholesterol
and HDL and LDL are clinically used as the parameters
for detection of several diseases. Lipid abnormalities are
associated with the incidence of coronary heart disease
and other cardiovascular diseases [26]. High LDL level
in the body can increase the risk of cardiac disease,
whilst low HDL level is an independent cardiovascular
risk factor. The increase of HDL by only 1 mg/dL can
lead to risk reduction of the disease. The contents of
HDL are proteins and lipids, including various glycero-
phospholipids, cholesteryl esters, sphingomyelins, free fattyacids, monoacylglycerols, diacylglycerols, triacylglycerols,
and different sphingolipids [27]. These compounds can be
profiled using global and targeted metabolomics approach.
HDL has the protective antiatherogenic properties, which
are independent of their involvement in cholesterol metab-
olism and it also reduces oxidation and vascular inflamma-
tion [28]. The ability to profile lipid metabolism in clinical
setting is thought to be useful as dysfunction of lipid
metabolism is associated with inflammation and oxidative
stress which significantly increased the risk of atheroscler-
otic cardiovascular diseases [29].
Of the fourteen potential biomarkers, we had detected
two metabolites with the highest value of AUC, sensitiv-
ity and specificity. They are 15(S)-HETE and phosphor-
ylcholine. 15(S)-HETE is a metabolite involved in the
metabolism of arachidonic acid and was found to be sig-
nificantly elevated in the patients as compared to the
healthy volunteers. Our findings were supported by the
earlier findings which showed that the elevated HETE
was found in the patients with heart diseases [30,31]. In
Figure 3 Quantitative evaluation of the diagnostic performance for putative biomarkers. Receiver operating characteristic (ROC) curve
analysis was performed to quantify the diagnostic performance of the nineteen candidate metabolites using PLSDA (A), Support Vector Machine
(SVM) (B) and Random Forest (RF) (C). The biomarkers were capable of discriminating the MI from HT with area under curve (AUC) of 0.998, 0.998
and 0.991, with average accuracy of 0.947, 0.961 and 0.963, respectively.
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Figure 4 Score plot of the PLSDA prediction model of the MI, HT and OA using identified biomarkers. A shows the PLSDA of MI and HT
while B shows the PLSDA of MI, HT and OA. OA data were added to the model for prediction resulted that several OA subjects were predicted
to have similar profiles with patients with cardiovascular diseases. The model was constructed according to the metabolites which have high
specificity and sensitivity (AUC >0.7).
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arachidonic acid metabolism is one of the pathways that
are involved in the alteration of the patient's metabolic
pathway. This metabolite is derived from omega-3 or
omega-6 polyunsaturated fatty acids. At the same time, it
is involved in the production of other metabolites, includ-
ing prostaglandins, thromboxanes, leukotrienes, epoxyei-
cosatrienoic acid and oxo-fatty acids. In cardiovascular
diseases, eicosanoids and fatty acids are probably involved
in the oxidative stress, inflammation, plaque formation
and pathogenesis [32,33], thus further strengthening the
relevance of 15(S)-HETE as a marker.
Another potential biomarker, phosphorylcholine, was
also found to be significantly elevated in the patients. This
metabolite was involved in two metabolic pathways, which
are the glycine, serine and threonine metabolism andglycerophospholipid metabolism pathway. In cardiovascu-
lar event, phosphorylcholine is a common epitope that
can be found in oxidized LDL. It plays an important role
in the post infarction setting by activating the endothelial
cells to recruit monocytes into the vascular wall leading to
inflammation and atherogenesis [34]. Phosphorylcholine
epitope is recognized by many parts of the innate im-
mune system, including B-lymphocytes, which release
natural antibodies such as IgM that work against phos-
phorylcholine [35]. Therefore the increased level of
phosphorylcholine denotes the process of inflammation
and atherogenesis among the patients and may be a
useful marker to monitor patients.
Our study also observed a significant decreased of
24,25-Dihydroxyvitamin D derivatives in patients as com-
pared to healthy volunteers. This result was supported by
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D in the heart disease patients [36]. It has been reported
that vitamin D deficiency was associated with high
BMI, cardiovascular diseases and obesity [37]. As most
of the Orang Asli are poorer in nutritional status and
have adopted sedentary lifestyles due to the relocation
programme, therefore their risks to CVD are increased.
Lower abundance of purine metabolites, specifically in-
osine were observed among the patients in this study. In-
osine is the precursor metabolite of deoxyadenosine and
uric acid. It is formed from the binding of hypoxanthine
and ribose. It is the intermediate product during the deg-
radation of purines and purine nucleosides to uric acid.
This is interestingly in accordance with the previous study
in an ischemic mouse heart model which showed that the
endogenous inosine might be a potential biomarker of ini-
tial cardiac ischaemia before cardiac tissue necrosis [38]. It
is believed that adenosine and inosine have the cardiopro-
tective effects. It was also reported that increase produc-
tion of adenosine and inosine by ischemic myocardium
supports the hypothesis that these cardiac nucleosides
may have important roles in the adaptation of coronary
blood flow in human coronary artery disease [39].
We also observed a significant difference of sphingoli-
pids metabolism between the patients and healthy volun-
teers. Sphingolipids are the minor components of lipid in
most mammalian cells. It is an important bioactive lipid
species which is involved in the pathogenesis of cardiovas-
cular diseases [40]. A metabolite of sphingolipids; C22 sul-
fatide was found to be significantly lower in the patients
as compared to the healthy volunteers. This result was
supported by Hu et al. [41] which reported the ability of
low level of serum sulfatides in initiating the development
of CVD. However, there are no significant correlation of
low sulfatide level with the measurements of HDL, LDL,
cholesterol and triacylglycerol.
Conclusion
Metabolomics-PLSDA risk prediction model was validated
and used to classify individuals based on their metabotypes.
In this study, the model was used for prediction of CVD
risks among the Orang Asli. Some of the Orang Asli with
self-claimed healthy status were shown to have metabolite
profiles similar to the patients. This shows that metabolo-
mics is a useful alternative to the routine biochemistry tests.
The metabolites differentiating the individuals into clus-
tered groups were shown to be good biomarkers with
high AUROC values, however, further validations are re-
quired before their use in clinical practise. More patients
related metabolomics database is needed to realise the use
of metabolomics which may be more cost effective in pro-
viding the wholesome metabolism picture of a patient at
real time. Concerted efforts from researchers are needed in
the setting up of clinical useful metabolome database.Additional files
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